A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, ABL2
Test Code39034
CPT Codes
88271 (x2), 88275
Preferred Specimen
3 mL bone marrow or 5 mL whole blood collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL bone marrow • 3 mL whole blood
Other Acceptable Specimens
Bone marrow collected in: Transport medium, sodium heparin (royal blue-top) tube, or sodium heparin lead-free (tan-top) tube • Whole blood collected in: Sodium heparin (royal blue-top) tube or sodium heparin lead-free (tan-top) tube
Instructions
Bone marrow transport medium is available upon request. Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided with test order.
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not Reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 7 days a week.
Report Available
Reports in 5 to 7 days.
Clinical Significance
High-risk B-ALL; BCR-ABL1-like B-ALL or Ph-like B-ALL with ABL class fusions diagnosis and evaluation for targeted therapy. Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as a BCR-ABL-1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of active kinase signaling. It exhibits adverse clinical features, confers poor prognosis and harbors a diverse range of genetic alterations that active cytokine receptors genes and kinase signaling pathways making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy.